Filing Flows › Indivior Pharmaceuticals (INDV) › Q3 2025
Indivior Pharmaceuticals (INDV) Q3 2025 earnings results (third quarter 2025)
10-Q filed Oct 30, 2025
Indivior Pharmaceuticals (INDV) reported revenue of $314M for the third quarter 2025 (Q3 2025), +2% from a year earlier and +4% from the quarter before. Operating margin was 13.7%, net earnings $42.0M (13.4% of revenue).
Indivior Pharmaceuticals, Q3 2025: revenue $314M (+2% year over year), operating margin 13.7%, net earnings $42.0M, operating cash flow −$39.0M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $314M | +4% | +2% |
| Gross profit | $230M | -8% | -5% |
| Operating profit | $43.0M | -40% | +23% |
| Net earnings | $42.0M | +133% | +91% |
| Operating cash flow | −$39.0M | -125% | — |
What changed
Revenue was $314.0M in Q3 2025, up 2% year over year and up 4% from the previous quarter.
Gross margin was 73.2%, down 5.3 points from a year earlier. Operating profit was $43.0M, a 13.7% margin (up 2.3 points year over year). Of the extra revenue versus a year earlier, 114% reached operating profit, above the 11% margin then. Operating expenses fell 9% while revenue rose 2%. The fastest-growing cost line was Research & development (+50%). Net earnings were $42.0M, up 91% year over year. The effective tax rate was -13.5%.
Operating cash flow was −$39.0M. Non-cash charges added back $3.0M of depreciation and amortization and $7.0M of share-based compensation. Working capital and other items used $91.0M. Capital expenditures of $20.0M exceeded it, leaving free cash flow of −$59.0M.
Questions
What was Indivior Pharmaceuticals' revenue in the third quarter 2025?
Indivior Pharmaceuticals (INDV) reported revenue of $314M for the third quarter 2025 (Q3 2025), +2% from a year earlier and +4% from the quarter before.
Was Indivior Pharmaceuticals profitable in the third quarter 2025?
Operating profit was $43.0M (13.7% of revenue) and net earnings $42.0M.